A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy and Safety of MK-1167 as Adjunctive Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia
Latest Information Update: 28 Jan 2025
Price :
$35 *
At a glance
- Drugs MK 1167 (Primary)
- Indications Alzheimer's disease; Dementia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 24 Dec 2024 Status changed from not yet recruiting to recruiting.
- 12 Dec 2024 New trial record